Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06001177 · ClinicalTrials.gov registry record · Phase 2
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
A Phase 2 study of Celiac Disease and Coeliac Disease, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT06001177: Completed Phase 2 study of Celiac Disease and Coeliac Disease, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
NCT06001177 is a Phase 2 study of Celiac Disease and Coeliac Disease that has completed, run by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion. The registered enrollment target is 55 participants, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 15 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06001177, a Phase 2 study of Celiac Disease and Coeliac Disease, has completed, sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Primary Outcome
KAN-101 attenuated GC-induced changes in duodenal histology as measured by the Vh:Cd ratio.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG KAN-101
Study Locations (20)
Quebec
- Centre Intégré de Santé et de Services Sociaux-Chaudière Appalaches - Hôtel-Dieu de Lévis - Lévis
- Hopital Du Sacre-Coeur De Montreal - Montreal
- Diex Recherche Quebec Inc. - Québec
Florida
- Unlimited Medical Research Group - Hialeah Gardens
- Homestead Associates in Research Inc. - Miami
Ontario
- McMaster University - Hamilton
- LHSC - London
Central District
- Rabin Medical Center - Petah Tikva
- Sheba Medical Center - Ramat Gan
Colorado
- Peak Gastroenterology Associates - Colorado Springs
Kansas
- Alliance for Multispecialty Research, LLC - Wichita
Louisiana
- Ochsner Clinic Foundation - New Orleans
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2025-01-13 |
| Phase | Phase 2 |
What the finished NCT06001177 record still lists
NCT06001177 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,978-participant average among 24 other Celiac Disease trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Celiac Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06001177 names 20 study sites across 15 states, led by Quebec, Florida, Ontario.
Frequently Asked Questions
What is clinical trial NCT06001177 about?
NCT06001177 is a clinical study titled "A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease". The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
What is the current status of trial NCT06001177?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2023-12-13. Estimated completion is 2025-01-13.
What conditions does trial NCT06001177 study?
This clinical trial studies the following conditions: Celiac Disease, Coeliac Disease.
What interventions are being tested in trial NCT06001177?
The interventions under investigation include: Placebo (DRUG), KAN-101 (DRUG).
Who is sponsoring clinical trial NCT06001177?
This trial is sponsored by Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06001177 being conducted?
This trial has 20 study locations across Colorado, Florida, Kansas, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Celiac Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06001177's enrollment target sits among peer trials
55 16th of 24 higher than 9 of 24 other Celiac Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Celiac Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission
RECRUITING · Phase 2
-
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
RECRUITING · Phase 2
-
Study of DONQ52 in Active Celiac Disease
RECRUITING · Phase 2
-
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
COMPLETED · Phase 2
-
Tissue Destruction and Healing in Celiac Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI